Brian Horsburgh, PhD
Brian Horsburgh is a molecular virologist with 25 years of biopharmaceutical industry experience, specifically in business development, venture capital, company building, IP management, and finance strategy. Most recently, he served as head of life sciences for IP Group (IPO:L), investing in innovative biotherapeutics and diagnostic companies. Prior to that he was a co-founder of Nurel Therapeutics which was acquired Diamyd Medical AB, and before that head of scientific affairs for NeuroVir Therapeutics which was acquired by MediGene AG. In addition to his role at Activate, he is the CEO of Immunova LLC, the parent company of Activate, and a Founding Partner at Neuronetworks Fund.
Brian was trained as a Postdoctoral Fellow at Harvard University, and earned his Ph.D. in Virology from the University of Cambridge.